Conor T. Ronayne

Synthesis and biological evaluation of glutathione-responsive 2-alkoxycarbonyl allyl niclosamide prodrugs as anticancer agents

This study synthesizes and evaluates glutathione-responsive niclosamide prodrugs as anticancer agents, showing reduced toxicity and tumor growth inhibition in mice.

Nitroxoline-O-protected derivatives inhibit MetAP2 and activate ATF4 through mTORC1 to inhibit cancer cell growth

The paper synthesizes nitroxoline analogs that inhibit MetAP2 and activate ATF4 via mTORC1, showing anti-cancer effects in vitro.

Synthesis and evaluation of novel N,N-dialkylcinnamic acid-based mitochondrial pyruvate carrier inhibitors: Biosynthetic and energetic lethality of targeting metabolic plasticity in cancer

The paper synthesizes and evaluates novel mitochondrial pyruvate carrier inhibitors for cancer treatment, showing activity in vitro and metabolic plasticity inhibition.

Silylation of hydroxychloroquine enhances autophagy inhibition and antiproliferative activity in breast and pancreatic cancer cells

This paper shows that silylating hydroxychloroquine improves its autophagy inhibition and antiproliferative effects in cancer cells.

Targeting tumor antioxidant pathways with novel GSTP1/M2 inhibitors for cancer treatment

This study designs and evaluates novel GSTP1/M2 inhibitors, finding that 5b effectively reduces tumor growth in vivo by overcoming gemcitabine resistance.

Development of fluoro-7-aminocarboxycoumarin-based mitochondrial pyruvate carrier inhibitors as anticancer agents

The paper develops novel fluoro-substituted aminocarboxycoumarin derivatives as mitochondrial pyruvate carrier inhibitors with anticancer potential.

Repurposing mitochondrial-targeting anthelmintic agents with GLUT1 inhibitor BAY-876 for cancer therapy

This study combines mitochondrial-targeting anthelmintics with a GLUT1 inhibitor to target cancer metabolism, showing enhanced efficacy by disrupting both glycolysis and mitochondrial respiration in breast cancer cells.